Miracle Mineral Supplement - MMS - Helps Relieve Chronic Pain

Navigation

Irritable Bowel Syndrome Links

Sucampo Pharma's Lubiprostone Meets Key Goal In Phase III Trial For OBD - Update

Rotating shift work may raise irritable bowel risk

Sucampo Pharma's Laxative Meets Key Goal In Phase III Trial For OBD - Update

Sucampo Gains as Bowel Drug Meets Study Goal: Washington Mover

Gazette.Net: Constipation drug offers more potential for Bethesdas Sucampo

<< 1 2 3 >>

Miracle Mineral Supplement - MMS - Helps Relieve Chronic Pain Recommended Products

Irritable Bowel Syndrome News

Sucampo Pharma's Lubiprostone Meets Key Goal In Phase III Trial For OBD - Update

Sucampo Pharmaceuticals Inc. (SCMP) and Takeda Pharmaceuticals U.S.A., Inc. announced Thursday that their drug lubiprostone, marketed under the trade name Amitiza, met the primary endpoint in a late-stage clinical trial for opioid-induced bowel dysfunction, or OBD.

Rotating shift work may raise irritable bowel risk

NEW YORK (Reuters Health) - Rotating shift work can wreak havoc with bodily functions such as sleep and bowel movements. Now study findings hint that rotating work schedules may also increase risk for irritable bowel syndrome.

Sucampo Pharma's Laxative Meets Key Goal In Phase III Trial For OBD - Update

Sucampo Gains as Bowel Drug Meets Study Goal: Washington Mover

Sucampo Pharmaceuticals Inc. surged 42 percent over two days after reporting that its experimental medicine for opioid-induced bowel dysfunction met goals in a late-stage clinical trial.

Gazette.Net: Constipation drug offers more potential for Bethesdas Sucampo

After a successful phase 3 clinical trial, Sucampo Pharmaceuticals of Bethesda is ready to apply for U.S. regulatory approval to market its constipation drug to people who have bowel dysfunction from taking morphine and codeine for chronic, non-cancer pain.

Home : Sitemap : Contact : Terms of Service : Privacy Policy